Marzia Bonsignore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marzia Bonsignore has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Irit Nachtigall
Department of Infectious Diseases and Infection Prevention, Helios Hospital Emil-von-Behring, 14165 Berlin, Germany
4 shared publications Irit Nachtigall
3 shared publications- Andreas Bollmann
Real World Evidence and Health Technology Assessment, Helios Health Institute, 13125 Berlin, Germany
2 shared publications - Cathrin Kodde
Department of Respiratory Diseases, Lungenklinik Heckeshorn, Helios Hospital Emil von Behring, Berlin, Germany
2 shared publications - Ralf Kuhlen
Helios Health, 13125 Berlin, Germany
2 shared publications - Sven Hohenstein
Clinical Trial Management & Real World Data, Helios Health Institute, 13125 Berlin, Germany
2 shared publications
Latest Publications
- 4 June 2025
- Published by Georg Thieme Verlag KG in Krankenhaushygiene up2date
- Vol. 20 (02) , 114-119
Schritt für Schritt: Anlage eines zentralen Venenkatheters aus hygienischer Sicht
Die Anlage eines zentralen Venenkatheters (ZVK) ist eine wesentliche Maßnahme in der perioperativen sowie in der Intensiv- und Notfallmedizin. Um Infektionen zu vermeiden, sind strenge Hygienemaßnahmen unerlässlich. Diese Anleitung erklärt Schritt für Schritt den korrekten Ablauf des Verfahrens unter besonderer Berücksichtigung der hygienischen Standards. Article published online: 04 June 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 4 June 2025
- Published by Georg Thieme Verlag KG in Krankenhaushygiene up2date
- Vol. 20 (02) , 114-119
Schritt für Schritt: Anlage eines zentralen Venenkatheters aus hygienischer Sicht
Die Anlage eines zentralen Venenkatheters (ZVK) ist eine wesentliche Maßnahme in der perioperativen sowie in der Intensiv- und Notfallmedizin. Um Infektionen zu vermeiden, sind strenge Hygienemaßnahmen unerlässlich. Diese Anleitung erklärt Schritt für Schritt den korrekten Ablauf des Verfahrens unter besonderer Berücksichtigung der hygienischen Standards. Article published online: 04 June 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- Open Access
Retrospective, Observational Analysis on the Impact of SARS-CoV-2 Variant Omicron in Hospitalized Immunocompromised Patients in a German Hospital Network—The VISAGE Study
Aims: Endemic SARS-CoV-2 infections still burden the healthcare system and represent a considerable threat to vulnerable patient cohorts, in particular immunocompromised (IC) patients. This study aimed to analyze the in-hospital outcome of IC patients with severe SARS-CoV-2 infection in Germany. Methods: This retrospective, observational study, analyzed administrative data from inpatient cases (n = 146,324) in 84 German Helios hospitals between 1 January 2022 and 31 December 2022 with regard to in-hospital outcome and health care burden in IC patients during the first 12 months of Omicron dominance. As the primary objective, in-hospital outcomes of patients with COVID-19-related severe acute respiratory infection (SARI) were analyzed by comparing patients with (n = 2037) and without IC diagnoses (n = 14,772). Secondary analyses were conducted on IC patients with (n = 2037) and without COVID-19-related SARI (n = 129,515). A severe in-hospital outcome as a composite endpoint was defined per the WHO definition if one of the following criteria were met: intensive care unit (ICU) treatment, mechanical ventilation (MV), or in-hospital death. Results: In total, 12% of COVID-related SARI cases were IC patients, accounting for 15% of ICU admissions, 15% of MV use, and 16% of deaths, resulting in a higher prevalence of severe in-hospital courses in IC patients developing COVID-19-related SARI compared to non-IC patients (Odds Ratio, OR = 1.4, p < 0.001), based on higher in-hospital mortality (OR = 1.4, p < 0.001), increased need for ICU treatment (OR = 1.3, p < 0.001) and mechanical ventilation (OR = 1.2, p < 0.001). Among IC patients, COVID-19-related SARI profoundly increased the risk for severe courses (OR = 4.0, p < 0.001). Conclusions: Our findings highlight the vulnerability of IC patients to severe COVID-19. The persistently high prevalence of severe outcomes in these patients in the Omicron era emphasizes the necessity for continuous in-hospital risk assessment and monitoring of IC patients.
Open AccessRetrospective, Observational Analysis on the Impact of SARS-CoV-2 Variant Omicron in Hospitalized Immunocompromised Patients in a German Hospital Network—The VISAGE Study
Aims: Endemic SARS-CoV-2 infections still burden the healthcare system and represent a considerable threat to vulnerable patient cohorts, in particular immunocompromised (IC) patients. This study aimed to analyze the in-hospital outcome of IC patients with severe SARS-CoV-2 infection in Germany. Methods: This retrospective, observational study, analyzed administrative data from inpatient cases (n = 146,324) in 84 German Helios hospitals between 1 January 2022 and 31 December 2022 with regard to in-hospital outcome and health care burden in IC patients during the first 12 months of Omicron dominance. As the primary objective, in-hospital outcomes of patients with COVID-19-related severe acute respiratory infection (SARI) were analyzed by comparing patients with (n = 2037) and without IC diagnoses (n = 14,772). Secondary analyses were conducted on IC patients with (n = 2037) and without COVID-19-related SARI (n = 129,515). A severe in-hospital outcome as a composite endpoint was defined per the WHO definition if one of the following criteria were met: intensive care unit (ICU) treatment, mechanical ventilation (MV), or in-hospital death. Results: In total, 12% of COVID-related SARI cases were IC patients, accounting for 15% of ICU admissions, 15% of MV use, and 16% of deaths, resulting in a higher prevalence of severe in-hospital courses in IC patients developing COVID-19-related SARI compared to non-IC patients (Odds Ratio, OR = 1.4, p < 0.001), based on higher in-hospital mortality (OR = 1.4, p < 0.001), increased need for ICU treatment (OR = 1.3, p < 0.001) and mechanical ventilation (OR = 1.2, p < 0.001). Among IC patients, COVID-19-related SARI profoundly increased the risk for severe courses (OR = 4.0, p < 0.001). Conclusions: Our findings highlight the vulnerability of IC patients to severe COVID-19. The persistently high prevalence of severe outcomes in these patients in the Omicron era emphasizes the necessity for continuous in-hospital risk assessment and monitoring of IC patients.
- Open Access
Impact of Dexamethasone on the Pathogen Profile of Critically Ill COVID-19 Patients
Background: Even though several therapeutic options are available, COVID-19 is still lacking a specific treatment regimen. One potential option is dexamethasone, which has been established since the early beginnings of the pandemic. The aim of this study was to determine its effects on the microbiological findings in critically ill COVID-19 patients. Methods: A multi-center, retrospective study was conducted, in which all the adult patients who had a laboratory-confirmed (PCR) SARS-CoV-2 infection and were treated on intensive care units in one of twenty hospitals of the German Helios network between February 2020–March 2021 were included. Two cohorts were formed: patients who received dexamethasone and those who did not, followed by two subgroups according to the application of oxygen: invasive vs. non-invasive. Results: The study population consisted of 1.776 patients, 1070 of whom received dexamethasone, and 517 (48.3%) patients with dexamethasone were mechanically ventilated, compared to 350 (49.6%) without dexamethasone. Ventilated patients with dexamethasone were more likely to have any pathogen detection than those without (p < 0.026; OR = 1.41; 95% CI 1.04–1.91). A significantly higher risk for the respiratory detection of Klebsiella spp. (p = 0.016; OR = 1.68 95% CI 1.10–2.57) and for Enterobacterales (p = 0.008; OR = 1.57; 95% CI 1.12–2.19) was found for the dexamethasone cohort. Invasive ventilation was an independent risk factor for in-hospital mortality (p < 0.01; OR = 6.39; 95% CI 4.71–8.66). This risk increased significantly in patients aged 80 years or older by 3.3-fold (p < 0.01; OR = 3.3; 95% CI 2.02–5.37) when receiving dexamethasone. Conclusion: Our results show that the decision to treat COVID-19 patients with dexamethasone should be a matter of careful consideration as it involves risks and bacterial shifts.
Open AccessImpact of Dexamethasone on the Pathogen Profile of Critically Ill COVID-19 Patients
Background: Even though several therapeutic options are available, COVID-19 is still lacking a specific treatment regimen. One potential option is dexamethasone, which has been established since the early beginnings of the pandemic. The aim of this study was to determine its effects on the microbiological findings in critically ill COVID-19 patients. Methods: A multi-center, retrospective study was conducted, in which all the adult patients who had a laboratory-confirmed (PCR) SARS-CoV-2 infection and were treated on intensive care units in one of twenty hospitals of the German Helios network between February 2020–March 2021 were included. Two cohorts were formed: patients who received dexamethasone and those who did not, followed by two subgroups according to the application of oxygen: invasive vs. non-invasive. Results: The study population consisted of 1.776 patients, 1070 of whom received dexamethasone, and 517 (48.3%) patients with dexamethasone were mechanically ventilated, compared to 350 (49.6%) without dexamethasone. Ventilated patients with dexamethasone were more likely to have any pathogen detection than those without (p < 0.026; OR = 1.41; 95% CI 1.04–1.91). A significantly higher risk for the respiratory detection of Klebsiella spp. (p = 0.016; OR = 1.68 95% CI 1.10–2.57) and for Enterobacterales (p = 0.008; OR = 1.57; 95% CI 1.12–2.19) was found for the dexamethasone cohort. Invasive ventilation was an independent risk factor for in-hospital mortality (p < 0.01; OR = 6.39; 95% CI 4.71–8.66). This risk increased significantly in patients aged 80 years or older by 3.3-fold (p < 0.01; OR = 3.3; 95% CI 2.02–5.37) when receiving dexamethasone. Conclusion: Our results show that the decision to treat COVID-19 patients with dexamethasone should be a matter of careful consideration as it involves risks and bacterial shifts.
- Open Access
Factors Influencing Antibody Response to SARS-CoV-2 Vaccination
Vaccination plays a key role in tackling the ongoing SARS-CoV-2 pandemic but data regarding the individual’s protective antibody level are still pending. Our aim is to identify factors that influence antibody response following vaccination in healthcare workers. This single-center study was conducted at Evangelische Kliniken Gelsenkirchen, Germany. Healthcare workers were invited to answer a questionnaire about their vaccinations and adverse reactions. Subsequently, the level of anti-receptor binding domain (RBD) IgG antibody against SARS-CoV-2′s spike protein through blood samples was measured. For statistics, we used a defined correlation of protection (CoP) and examined risk factors associated with being below the given CoP. A total of 645 employees were included and most were female (n = 481, 77.2%). A total of 94.2% participants had received two doses of vaccines (n = 587) and 12.4% (n = 720) had been infected at least once. Most common prime-boost regimen was BNT162b2 + BNT162b2 (57.9%, n = 361). Age (p < 0.001), days since vaccination (p = 0.007), and the homologous vaccination regimen with ChAdOx + ChAdOx (p = 0.004) were risk factors for the antibody level being below the CoP, whereas any previous COVID-19 infection (p < 0.001), the number of vaccines (p = 0.016), and physical complaints after vaccination (p = 0.01) were associated with an antibody level above the CoP. Thus, age, vaccination regimen, days since vaccination, and previous infection influence the antibody level. These risk factors should be considered for booster and vaccinations guidelines.
Open AccessFactors Influencing Antibody Response to SARS-CoV-2 Vaccination
Vaccination plays a key role in tackling the ongoing SARS-CoV-2 pandemic but data regarding the individual’s protective antibody level are still pending. Our aim is to identify factors that influence antibody response following vaccination in healthcare workers. This single-center study was conducted at Evangelische Kliniken Gelsenkirchen, Germany. Healthcare workers were invited to answer a questionnaire about their vaccinations and adverse reactions. Subsequently, the level of anti-receptor binding domain (RBD) IgG antibody against SARS-CoV-2′s spike protein through blood samples was measured. For statistics, we used a defined correlation of protection (CoP) and examined risk factors associated with being below the given CoP. A total of 645 employees were included and most were female (n = 481, 77.2%). A total of 94.2% participants had received two doses of vaccines (n = 587) and 12.4% (n = 720) had been infected at least once. Most common prime-boost regimen was BNT162b2 + BNT162b2 (57.9%, n = 361). Age (p < 0.001), days since vaccination (p = 0.007), and the homologous vaccination regimen with ChAdOx + ChAdOx (p = 0.004) were risk factors for the antibody level being below the CoP, whereas any previous COVID-19 infection (p < 0.001), the number of vaccines (p = 0.016), and physical complaints after vaccination (p = 0.01) were associated with an antibody level above the CoP. Thus, age, vaccination regimen, days since vaccination, and previous infection influence the antibody level. These risk factors should be considered for booster and vaccinations guidelines.
- Open Access
- 17 November 2022
- Published by Springer Nature
- p. 171-187
Arzneimittelnutzung unter Pandemiebedingungen
- 17 November 2022
- Published by Springer Nature
- p. 171-187
Open AccessArzneimittelnutzung unter Pandemiebedingungen
- 17 August 2022
- Published by Georg Thieme Verlag KG in Krankenhaushygiene up2date
- Vol. 17 (03) , 213-216
Bronchoskopie unter hygienischen Aspekten – Schritt für Schritt
Die flexible Bronchoskopie gehört mit der Messung der Lungenfunktion und der radiologischen Bildgebung zu den wesentlichen diagnostischen Mitteln bei Patient*innen mit Atemwegs- und Lungenerkrankungen, aber auch zur Diagnostik bei Verdacht auf Lungenkrebs. Durch kontinuierliche, technische Weiterentwicklungen dient sie darüber hinaus zunehmend der Therapie, z.B. zur Bronchialtoilette vor allem auf der Intensivstation, oder zur Entfernung von Fremdkörpern. Article published online: 17 August 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 17 August 2022
- Published by Georg Thieme Verlag KG in Krankenhaushygiene up2date
- Vol. 17 (03) , 213-216
Bronchoskopie unter hygienischen Aspekten – Schritt für Schritt
Die flexible Bronchoskopie gehört mit der Messung der Lungenfunktion und der radiologischen Bildgebung zu den wesentlichen diagnostischen Mitteln bei Patient*innen mit Atemwegs- und Lungenerkrankungen, aber auch zur Diagnostik bei Verdacht auf Lungenkrebs. Durch kontinuierliche, technische Weiterentwicklungen dient sie darüber hinaus zunehmend der Therapie, z.B. zur Bronchialtoilette vor allem auf der Intensivstation, oder zur Entfernung von Fremdkörpern. Article published online: 17 August 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 June 2022
- Published by Georg Thieme Verlag KG in OP-Management up2date
- Vol. 2 (02) , 153-164
Infektionsprävention in der Anästhesie
Zur anästhesiologischen Versorgung im OP zählen viele Tätigkeiten, die mit einem Infektionsrisiko für Patienten einhergehen. Diejenigen Momente, die eine besondere Gefahr für die Entstehung einer behandlungsassoziierten Infektion beherbergen, müssen bekannt und die dazugehörigen Präventionsmaßnahmen etabliert sein. Nur so kann verhindert werden, dass es insbesondere in Stresssituationen zu Hygienefehlern kommt und Patienten gefährdet werden. Article published online: 03 August 2022 © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 June 2022
- Published by Georg Thieme Verlag KG in OP-Management up2date
- Vol. 2 (02) , 153-164
Infektionsprävention in der Anästhesie
Zur anästhesiologischen Versorgung im OP zählen viele Tätigkeiten, die mit einem Infektionsrisiko für Patienten einhergehen. Diejenigen Momente, die eine besondere Gefahr für die Entstehung einer behandlungsassoziierten Infektion beherbergen, müssen bekannt und die dazugehörigen Präventionsmaßnahmen etabliert sein. Nur so kann verhindert werden, dass es insbesondere in Stresssituationen zu Hygienefehlern kommt und Patienten gefährdet werden. Article published online: 03 August 2022 © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 25 February 2022
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 119 (8) , 134
Correspondence
- 25 February 2022
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 119 (8) , 134
Correspondence